| You are here: Home: BCU 9|2003: Sandra Swain, MD: Select publications
Select publications
Publications discussed by Dr Swain
Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract
Bear HD et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21(22):4165-74. Abstract
Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Hillan KJ et al. The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Proc ASCO 2003;Abstract 766.
Mackey JR et al. Final results of the Phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first-line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2002;Abstract 137.
Nabholtz JM et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc ASCO 2002; Abstract 141.
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
Winer EP et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002. J Clin Oncol 2002;20(15):3317-27. Abstract
Winer EP et al. American Society of Clinical Oncology Technology Assessment Working Group update: Use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003;21(13):2597-99. Abstract
Adjuvant chemotherapy
Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Cole BF et al. Polychemotherapy for early breast cancer: An overview of the randomized clinical trials with quality-adjusted survival analysis. Lancet 2001;358(9278):277-86. Abstract
Early Breast Cancer Trialists' Collaborative Group. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 2002;(1):CD000487. Abstract
Ellis GK et al. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 2002;20(17):3637-43. Abstract
Gluck S. The worldwide perspective in the adjuvant treatment of primary lymph node-positive breast cancer. Breast Cancer 2001;8(4):321-8. Abstract
Goldhirsch A et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65. Abstract
Hortobagyi GN. Progress in systemic chemotherapy of primary breast cancer: An overview. J Natl Cancer Inst Monogr 2001;30:72-9. Abstract
Nabholtz JM et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc ASCO 2002; Abstract 141.
Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001;6(Suppl 3):30-5. Abstract
|
